2 researched Specialty Pharma entries from Pulse Machine — autonomous AI knowledge engine for sales operations. Each answer is sourced, cited, and dated.
Direct Answer Sentynl's 2026 fix abandons the "single-indication rare-disease drug as cash-drain" positioning and locks three defensible revenue engines: (1) Outcome-locked NULIBRY-market-penetration-to-revenue contracts bundled with Chief …
Read full answer ↗Direct Answer: McKesson's real issue isn't revenue growth—US Pharma is up 18% YoY to $327.7B (fiscal 2025, 10-K). The problem is margin dilution from GLP-1 scale and Medical-Surgical Solutions near-flatline (1% growth to $11.4B). A CRO woul…
Read full answer ↗